Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
7
Next >
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 28, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Date of Annual Meeting of Shareholders
July 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
July 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
June 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
June 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
June 09, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Acquires DMT Clinical Study from Entheon Biomedical
June 07, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
May 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
May 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
May 05, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
April 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
April 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
April 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
April 01, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
March 31, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
March 29, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
March 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
March 24, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
March 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
February 18, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
February 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.